BACKGROUND: Cytochrome P450 (CYP) 2J2 is expressed in the vascular endothelium and metabolizes arachidonic acid to biologically active epoxyeicosatrienoic acids (EETs). The EETs are potent endogenous vasodilators and inhibitors of vascular inflammation. However, it is not known whether genetic polymorphisms of CYP2J2 are associated with increased cardiovascular risks. METHODS AND RESULTS: All 9 exons of the CYP2J2 gene and its proximal promoter were sequenced in 132 patients to identify potential variants. Functional consequence of a single nucleotide polymorphism (SNP) in the promoter of CYP2J2 was further evaluated by use of transcription factor-binding and reporter assays. A total of 17 polymorphisms were identified. One of the most relevant polymorphisms in terms of frequency and functional importance is located at -50 (G-50T) in the proximal promoter of CYP2J2. Screening of 289 patients with coronary artery disease and 255 control subjects revealed 77 individuals with the G-50T SNP (17.3% of coronary artery disease patients, 10.6% of control subjects; P=0.026). The association of the G-50T polymorphism remained significant after adjustment for age, gender, and conventional cardiovascular risk factors (OR, 2.23; 95% CI, 1.04 to 4.79). The G-50T mutation resulted in the loss of binding of the Sp1 transcription factor to the CYP2J2 promoter and resulted in a 48.1+/-2.4% decrease in CYP2J2 promoter activity (P<0.01). Plasma concentrations of stable EET metabolites were significantly lower in individuals with the G-50T SNP. CONCLUSIONS: A functionally relevant polymorphism of the CYP2J2 gene is independently associated with an increased risk of coronary artery disease.
BACKGROUND:Cytochrome P450 (CYP) 2J2 is expressed in the vascular endothelium and metabolizes arachidonic acid to biologically active epoxyeicosatrienoic acids (EETs). The EETs are potent endogenous vasodilators and inhibitors of vascular inflammation. However, it is not known whether genetic polymorphisms of CYP2J2 are associated with increased cardiovascular risks. METHODS AND RESULTS: All 9 exons of the CYP2J2 gene and its proximal promoter were sequenced in 132 patients to identify potential variants. Functional consequence of a single nucleotide polymorphism (SNP) in the promoter of CYP2J2 was further evaluated by use of transcription factor-binding and reporter assays. A total of 17 polymorphisms were identified. One of the most relevant polymorphisms in terms of frequency and functional importance is located at -50 (G-50T) in the proximal promoter of CYP2J2. Screening of 289 patients with coronary artery disease and 255 control subjects revealed 77 individuals with the G-50T SNP (17.3% of coronary artery diseasepatients, 10.6% of control subjects; P=0.026). The association of the G-50T polymorphism remained significant after adjustment for age, gender, and conventional cardiovascular risk factors (OR, 2.23; 95% CI, 1.04 to 4.79). The G-50T mutation resulted in the loss of binding of the Sp1 transcription factor to the CYP2J2 promoter and resulted in a 48.1+/-2.4% decrease in CYP2J2 promoter activity (P<0.01). Plasma concentrations of stable EET metabolites were significantly lower in individuals with the G-50T SNP. CONCLUSIONS: A functionally relevant polymorphism of the CYP2J2 gene is independently associated with an increased risk of coronary artery disease.
Authors: Ning Li; Jun-Yan Liu; Hong Qiu; Todd R Harris; Padmini Sirish; Bruce D Hammock; Nipavan Chiamvimonvat Journal: Congest Heart Fail Date: 2011-01-27
Authors: Eric A Evangelista; Rüdiger Kaspera; Nahush A Mokadam; J P Jones; Rheem A Totah Journal: Drug Metab Dispos Date: 2013-09-10 Impact factor: 3.922
Authors: Craig R Lee; Kari E North; Molly S Bray; Myriam Fornage; John M Seubert; John W Newman; Bruce D Hammock; David J Couper; Gerardo Heiss; Darryl C Zeldin Journal: Hum Mol Genet Date: 2006-04-04 Impact factor: 6.150
Authors: Tracy C Delozier; Grace E Kissling; Sherry J Coulter; Diana Dai; Julie F Foley; J Alyce Bradbury; Elizabeth Murphy; Charles Steenbergen; Darryl C Zeldin; Joyce A Goldstein Journal: Drug Metab Dispos Date: 2007-01-12 Impact factor: 3.922
Authors: Tong Lu; Dan Ye; Xiaoli Wang; John M Seubert; Joan P Graves; J Alyce Bradbury; Darryl C Zeldin; Hon-Chi Lee Journal: J Physiol Date: 2006-06-22 Impact factor: 5.182
Authors: Craig R Lee; Kari E North; Molly S Bray; David J Couper; Gerardo Heiss; Darryl C Zeldin Journal: Pharmacogenet Genomics Date: 2007-05 Impact factor: 2.089
Authors: Pierre Lafite; Sylvie Dijols; Darryl C Zeldin; Patrick M Dansette; Daniel Mansuy Journal: Arch Biochem Biophys Date: 2007-04-10 Impact factor: 4.013